Pharma Sector Updates: Biocon, Lupin, Medi Assist, and Dr Reddy’s Face Regulatory Actions and Investments
Biocon's newly inaugurated US manufacturing facility in Cranbury, New Jersey, underwent a GMP inspection by the US FDA, concluding with one observation. The company assured stakeholders the issue WOULD be resolved promptly without operational impact.
Lupin Ltd's Somerset facility faced a Pre-Approval Inspection by the US FDA, resulting in a single observation. The firm committed to addressing the finding within the regulatory timeline.
Medi Assist Healthcare Services secured a ₹198 crore investment through preferential allotment from MIT and 238 Plan Associates LLC, issuing shares at ₹535 apiece to strengthen its capital base.
Dr Reddy's Laboratories and Zydus Lifesciences initiated product recalls in the US market following manufacturing concerns flagged by regulators, underscoring ongoing compliance challenges in the sector.
